PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12734647-6	2003	INTERVENTIONS: Nine pretreated dogs received an infusion of the endothelin A and B receptor antagonist bosentan (10 mg/kg) started before oleic acid.	Bosentan	103-111	endothelin receptor type A	Canis lupus familiaris	64-91	
9792992-1	1998	BACKGROUND: As endothelin-1 exerts positive inotropic effects, the present study evaluated whether the hypotensive effects of the endothelin-1 receptor antagonist bosentan were partially related to a decrease in myocardial performance.	Bosentan	163-171	endothelin receptor type A	Canis lupus familiaris	130-151	
9663924-1	1998	OBJECTIVE: To evaluate whether the cumulative hypotensive effect of the endothelin-1 receptor antagonist bosentan, previously demonstrated in the presence of an angiotensin converting enzyme inhibitor, persists under angiotensin II receptor blockade with losartan.	Bosentan	105-113	endothelin receptor type A	Canis lupus familiaris	72-93	
8772702-2	1996	In the present study, we examined the effects of intravenous bosentan, a nonpeptide, competitive endothelin-1 receptor antagonist, on hemodynamics in dogs with chronic heart failure.	Bosentan	61-69	endothelin receptor type A	Canis lupus familiaris	97-118	
9861300-0	1998	Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.	Bosentan	53-61	endothelin receptor type A	Canis lupus familiaris	20-41	
7840293-3	1995	Big ET induced peripheral and coronary vasoconstriction, which occurred before significant elevations in plasma ET and which was nearly completely blocked by bosentan, a new nonpeptidic mixed (ETA and ETB) ET receptor antagonist.	Bosentan	158-166	endothelin receptor type A	Canis lupus familiaris	193-196